Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Caligaris-Cappio

Showing results (121-130 of 128) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 128 results.
British Journal of Cancer|August 19, 2010
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinomaA Santoro, T Pressiani, G Citterio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2012
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)M Ghielmini, U Vitolo, E Kimby, et al.
International Journal of Clinical & Laboratory Research|August 5, 1998
The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapyF Dammacco, F Silvestris, G L Castoldi, et al.
Neurology|May 10, 2006
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomasA J M Ferreri, S Dell'Oro, M Foppoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1990
Interferons in the treatment of multiple myelomaD E Bergsagel, P von Wussow, R Alexanian, et al.
Leukemia|March 16, 2007
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaA C Rawstron, N Villamor, M Ritgen, et al.
Leukemia|June 9, 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLLJ R Brown, P Hillmen, S O'Brien, et al.
Lancet (London, England)|October 5, 2010
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialM Hallek, K Fischer, G Fingerle-Rowson, et al.
Pageof 13

Showing results (121-130 of 128) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 128 results.
British Journal of Cancer|August 19, 2010
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinomaA Santoro, T Pressiani, G Citterio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2012
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)M Ghielmini, U Vitolo, E Kimby, et al.
International Journal of Clinical & Laboratory Research|August 5, 1998
The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapyF Dammacco, F Silvestris, G L Castoldi, et al.
Neurology|May 10, 2006
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomasA J M Ferreri, S Dell'Oro, M Foppoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1990
Interferons in the treatment of multiple myelomaD E Bergsagel, P von Wussow, R Alexanian, et al.
Leukemia|March 16, 2007
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaA C Rawstron, N Villamor, M Ritgen, et al.
Leukemia|June 9, 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLLJ R Brown, P Hillmen, S O'Brien, et al.
Lancet (London, England)|October 5, 2010
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialM Hallek, K Fischer, G Fingerle-Rowson, et al.
Pageof 13